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Abstract
The mammalian target of rapamycin (mTOR) signaling network is frequently hyperactivated in patients with head
and neck squamous cell carcinoma (HNSCC). Recent studies suggest that hypoxia, a common microenvironmen-
tal stress found in tumors, blocks this mitogenic pathway. Here, we demonstrate that in HNSCC cell lines, the
expression of the phosphorylated forms of the mTOR downstream targets S6 kinase and S6 (pS6) decreased after
hypoxia. These events were associated with a marked up-regulation of the regulated in development and DNA
damage 1 (REDD1), a recently characterized hypoxia-induced protein that negatively controls mTOR activity. Con-
versely, pS6 levels were retained under hypoxia in REDD1 knock-down cells and in HNSCC cells lacking endoge-
nous REDD1 expression. Furthermore, we observed that prolonged hypoxia induced an energy-depleting response
as evidenced by decreased cellular ATP levels and AMP-activated protein kinase (AMPK) activation. Interestingly,
AMPK inhibition before prolonged hypoxia prevented REDD1 expression, thereby sustaining mTOR activity. These
results suggest a novel mechanism by which AMPK activation after hypoxia-induced energy stress may be crucial
in regulating REDD1 expression to control the mTOR pathway in HNSCC. Furthermore, we found that, in some
HNSCC cells, the reduced mTOR activity in response to hypoxia through AMPK/REDD1 was deregulated, which
hence might contribute to the persistent activation of the mTOR pathway in this cancer type.
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Introduction
Cancer development is frequently initiated by genetic alterations af-
fecting cell growth–promoting as well as tumor-suppressive signaling
networks in conjunction with epigenetic disturbances and progresses
by the constant adaptation of tumor cells to microenvironmental
selective pressures [1,2]. Microenvironmental stresses such as poor
oxygenation or hypoxia arising in part by the structural and func-
tional abnormalities affecting the vasculature are commonly found
within the heterogeneous regions of expanding solid tumors [3]. This
is particularly evident in head and neck squamous cell carcinomas
(HNSCC), including those of the oral cavity and pharynx, where
the extent of intratumoral hypoxia plays an important prognostic
factor as it relates to cancer aggressiveness, chemoradiotherapy resis-
tance, and overall patient survival [4–6].
The availability of molecular oxygen also plays a critical role in con-
trolling signaling pathways responsible for relaying nutrient- and
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energy-sensing cues to control cellular programs commonly involved
in human cancer such as cell proliferation, differentiation, and sur-
vival [7]. Among these, the Akt/mammalian target of rapamycin
(mTOR) pathway seems to be a major regulator of the cellular re-
sponses to hypoxia and other microenvironmental stresses [8]. Acting
as a positive central integrator of mitogenic signals, the evolutionarily
conserved serine/threonine protein kinase mTOR transmits stimula-
tory cues for protein synthesis and cell growth by phosphorylating
key downstream substrates involved in protein translation, including
the eukaryotic initiation factor 4E-binding protein-1 (4EBP1) and
ribosomal p70 S6 kinase (S6K). This occurs after the sequential acti-
vation of phosphoinositide-3-kinase (PI3K) and the serine/threonine
kinase Akt in response to a myriad of cell surface molecules includ-
ing growth factors, hormones, and extracellular matrix components.
However, in an attempt to preserve cellular energy consumption,
mTOR activity is attenuated in response to cellular stresses, such
as hypoxia, through activation of the tuberous sclerosis complex 1/2
(TSC1/TSC2) tumor-suppressor complex. TSC2 functions as a
GTPase-activating protein antagonizing the small GTPase Rheb act-
ing upstream of mTOR. During permissive conditions, the Rheb-
GAP activity of TSC2 is kept inactive by an Akt-driven inhibitory
phosphorylation, leading to the accumulation of active GTP-bound
Rheb, which in turn phosphorylates and activates mTOR [8–11].
These observations suggest that any aberration impinging on the
TSC1/2 complex-activating network may result in an abnormally high
mTOR activity.
Interestingly, emerging information points to the mTOR signaling
network as frequently altered in human HNSCC and its derived cell
lines [12–16]. Thus, it is plausible that in those human HNSCC that
are dependent on aberrantly high mTOR activity, the hypoxia-driven
inhibitory mechanisms responsible for down-regulating this pathway
might be impaired. This possibility prompted us to explore whether
hypoxic responses controlled by the TSC complex/mTOR signaling
cascade may be deregulated in HNSCC. In this regard, the identifica-
tion of the regulated in development and DNA damage 1 (REDD1)
gene as a novel repressor of mTOR activity in both mammalian and
Drosophila cells has provided a key component to the stress-response
pathway negatively affecting mTOR function. REDD1 encodes a
232–amino acid cytosolic protein (∼34 kDa) with unknown func-
tional domains. REDD1-mediated inhibition of mTOR is stimulated
in cells exposed to hypoxia as well as in cells undergoing energy stress
and is dependent on the presence of a functional TSC1/TSC2
tumor-suppressor complex [17–20]. An additional pathway by which
energy stress can result in mTOR inhibition is mediated by a positive
TSC2-phosphorylating event initiated by the cellular energy-sensing
apparatus through the AMP-activated kinase (AMPK) [21]. The
AMPK is the downstream target of the serine/threonine kinase LKB1,
a product of the LKB1 gene whose hereditary inactivation is respon-
sible for the cancer-prone Peutz-Jeghers syndrome [22]. Here, we
show that, in HNSCC, these two mechanisms are highly interre-
lated. Indeed, we observed that AMPK activation controls REDD1
expression in response to prolonged hypoxia and that this biochem-
ical route by which hypoxia-induced energy stress can reduce mTOR
activity is disrupted in some HNSCC cells. Our results suggest that
under metabolic stress triggered by energy depletion in response to
hypoxia, the AMPK energy-sensing apparatus and REDD1 might be
linked in the regulation of mTOR activity in human HNSCC and
that the dysfunction of this mechanism by which hypoxia inhibits
mTOR activity may contribute to HNSCC progression.
Materials and Methods
Cell Culture and Reagents
The HNSCC cell lines HN6, HN12, and HN13 [23] were grown
andmaintained in 10%FBS, 1% antibiotic/antimycotic DMEM.Un-
less otherwise stated, HNSCC cells were serum-starved for 24 hours
before any treatment. When indicated, serum-deprived HNSCC cells
were pretreated for 30 minutes with compound C (Calbiochem,
Gibbstown, NJ), a potent AMPK inhibitor, or vehicle control and
then cultured under normoxic or hypoxic conditions. When required,
cells were also treated with 2-deoxy-D-glucose (2-DG; Calbiochem). Re-
combinant human epidermal growth factor (EGF) was purchased
from PeproTech (Rocky Hill, NJ). Hypoxic conditions were generated
by placing cells in a modular incubator chamber (Billups-Rottenberg,
Inc., Del Mar, CA) containing 1% O2, 5% CO2, and 94% nitrogen.
Normoxic cells were grown at 37°C in the presence of 5% CO2.
Immunohistochemistry
Human HNSCC tissue sections were obtained from the Head and
Neck Cancer Tissue Array Repository [15] under a National Insti-
tutes of Health–approved research activity involving human subjects.
Tissue slides were dewaxed in xylene, hydrated through graded al-
cohols and distilled water, and washed thoroughly in PBS. Antigen
retrieval was done using 10 mM citrate buffer (pH 6) in a microwave
(20 minutes). After incubation with 3% hydrogen peroxide in PBS
(30 minutes), slides were washed in PBS and incubated in block-
ing solution (2.5% BSA in PBS) for 1 hour at room temperature.
Sections were then incubated with the primary antibodies: mouse
monoclonal anti–Glut-1 at 1:200 (Abcam, Cambridge, MA) and
rabbit monoclonal anti–phospho-S6 ribosomal protein (Ser235/
236) at 1:100 (Cell Signaling Technology, Danvers, MA) diluted
in blocking solution overnight at 4°C. After washing with PBS,
slides were incubated with biotinylated secondary antibodies (1 hour;
1:400), followed by the ABC complex (Vector Stain Elite, ABC kit;
Vector Laboratories, Burlingame, CA) for 30 minutes. Slides were
washed and developed in 3,3-diaminobenzidine under microscope
control and counterstaining with Mayer’s hematoxylin. Images were
acquired using a microscope (Axioplan 2; Carl Zeiss, Thornwood,
NY). Semiquantitative analysis was performed by two independent ex-
aminers to characterize the relative regional distribution of Glut-1
and phosphorylated ribosomal protein S6 (pS6) immunostaining in
cells centrally localized in tumor islands (n = 5).
ATP Assay
The detection of ATP levels in whole cell extracts was assessed by
using a luminescence-based ATP assay kit (Calbiochem).
RNA Interference
HN13 cells were plated at 15,000 cells/cm2 overnight. The fol-
lowing day, transfections were performed by using the following
reagents: short interfering RNA (siRNA) duplexes (Qiagen, Valencia,
CA) targeting REDD1 (Hs_DDIT4_1_HP siRNA; SI00360773),
hypoxia-inducible factor (HIF) 1α (Hs_HIF1A_1_1HP siRNA;
SI00436296), or HIF-2α (Hs_EPAS1_1_HP siRNA; SI00380205)
were transfected with Hiperfect transfection reagent (Qiagen) in com-
plete medium following the manufacturer’s recommendations. Like-
wise, a commercially available pool of three target-specific siRNAs
(sc-45312; Santa Cruz Biotechnology, Santa Cruz, CA) were used
to knock down the α1 and α2 catalytic subunits of the human
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AMPK gene following the siRNA transfection protocol of the man-
ufacturer. Untransfected cells and cells transfected with a negative
control siRNA (Qiagen) were included in all experiments. The next
day following transfections, cells were serum-starved for 24 hours
and then exposed to either normoxia or hypoxia for 18 hours.
Western Blot Analysis
After the indicated experiments, mediumwas removed and HNSCC
cell monolayers were rinsed with ice-cold Dulbecco’s phosphate-
buffered saline and rapidly lysed with protein lysis buffer [62.5 mM
Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 50 mM DTT]. Lysates
were sonicated for 20 seconds, and protein concentration was de-
termined using the Bradford reagent (Sigma, St. Louis, MO). Equal
amounts of protein were separated by SDS-PAGE and electrophoret-
ically transferred onto polyvinylidene difluoride membranes (BioRad,
Hercules, CA). Appropriate transfer and equivalent loading was con-
firmed by staining membranes with Ponceau S red solution (Sigma).
Membranes were blocked in blocking buffer (5% nonfat dry milk in
0.05% Tween 20–TBS) for 1 hour and then replaced by the primary
antibody diluted in blocking buffer for 2 hours at room temperature
or overnight at 4°C, depending on the specific antibody. The follow-
ing primary antibodies were used: rabbit polyclonal against phospho-
S6 Ser240/244, phospho-Akt (Ser473), phospho-p70 S6 kinase
(Thr389), and phospho-acetyl CoA carboxylase (Ser79) and rabbit
monoclonal against S6, phospho-Akt (Thr308), and phospho-AMPKα
(Thr172) were purchased from Cell Signaling Technology and used at
1:1000 dilution. Rabbit polyclonal anti-REDD1 (1:500) was obtained
from Proteintech Group (Chicago, IL). Mouse monoclonal anti–HIF-
1α (1:500) and rabbit polyclonal anti–HIF-2α (1:250) were purchased
from Novus Biologicals (Littleton, CO). Mouse monoclonal anti–α-
tubulin (1:1000) was purchased from Santa Cruz Biotechnology.
Rabbit polyclonal anti-GAPDH (1:5000) was obtained from Sigma.
After washing membranes three times in washing buffer, primary anti-
bodies were detected using horseradish peroxidase–linked sheep anti–
mouse or donkey anti–rabbit IgG antibodies at 1:10,000 dilution
(Amersham, Piscataway, NJ) and visualized by chemiluminescence.
Statistics
The data were analyzed using Student’s t test with the Instat 3.0
biostatistics program (GraphPad Software, La Jolla, CA). Data are
presented as mean ± SEM.
Results
Hypoxia Inhibits the mTOR Signaling Pathway in HNSCC.
Disruption of This Mechanism in Certain HNSCC Cells
The aberrant activation of the PI3K/Akt/mTOR pathway seems to
be a frequent event in human HNSCC and its derived cell lines
[12,13,15,16]. Accumulating evidence indicates that mTOR activity
is negatively regulated by hypoxia, a common microenvironmental
condition present in growing solid tumors. Despite the frequent hy-
peractivation of the mTOR pathway in HNSCC, the intervening
molecules affected by hypoxia in this cancer type have remained
largely unexplored. Indeed, we noticed that in tumor islands from
human HNSCC tissues, the pattern of regional distribution of the
hypoxia-regulated glucose transporter Glut-1–stained tumor cells
seems to be inversely correlated to the localization of cells positively
stained with the phosphorylated active form of the ribosomal protein
S6 (pS6), a downstream mTOR target. Membrane-bound Glut-1 lo-
calization and staining in centrally localized tumor cells, which are
most likely hypoxic, were significantly increased when compared to
the periphery where more pS6-positive cells were present (Figure 1).
Because the mechanisms controlling the mTOR pathway in response
to hypoxic stress are still not well defined, we were prompted to fur-
ther explore which key intervening factors regulate the activity of the
mTOR pathway in HNSCC cell lines. To perform these experi-
ments, we took advantage of the availability of HNSCC cell lines
known to have increased basal mTOR activity as evidenced by the
high pS6 expression levels [12,13]. Unexpectedly, we observed a
variable effect on the mTOR pathway when these cell lines were cul-
tured under hypoxia (1% O2 for 18 hours) in serum-free conditions.
Although hypoxia induced a marked reduction in pS6 levels in HN13
and HN12 cells, the effects on pS6 in HN6 cells were unaltered
Figure 1. Intratumoral hypoxia correlates with reduced mTOR activation in human HNSCC. Moderate to intense immunodetection of the
hypoxia marker Glut-1 (A: subpanels a–c) was frequently found in areas where the activation status of the mTOR downstream target S6
(pS6) was reduced or absent (A: subpanels d–f). Immunohistochemistry was performed on tissue sections from representative human
HNSCC specimens using antibodies against Glut-1 and pS6 to determine the effects of regional intratumoral hypoxia on the mTOR
pathway in vivo. (B) In hypoxic foci, the relative distribution of Glut-1 immunostaining was significantly increased when compared to
tumor cells positively stained with pS6 (*P < .05). Data represent the mean ± SEM.
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and remained similar to the levels observed under normoxic condi-
tions, suggesting that these cells were tolerant to the inhibitory effects
exerted by hypoxic stress on mTOR activity (Figure 2A). Because
the PI3K/Akt pathway is implicated in the control of mTOR activity
in response to growth factor–mediated inputs, it might be possible
that the effects on the mTOR pathway were directly related to Akt
inhibition associated with serum-deprived conditions rather than
hypoxic stress per se. As shown in Figure 2B, the presence or absence
of serum in the culture medium had little effect on the phosphor-
ylated status of Akt in HNSCC cell lines. The only significant dif-
ference was observed in HN13 cells cultured under serum-repleted
conditions where hypoxia induced substrate dephosphorylation of
both AktS473 and AktT308.
REDD1 Is Required to Inhibit mTOR Activity in Response to
Hypoxia in HNSCC Cells
Recent studies have identified REDD1, a stress-induced gene act-
ing upstream of the TSC1/TSC2 tumor-suppressor complex, as a key
molecule within an inhibitory cascade targeting mTOR activity in
response to hypoxia [18,24]. Because the effects of hypoxia on the
mTOR pathway seemed to be dissimilar among HNSCC cell lines,
we hypothesized that the lack of hypoxia-induced inhibition of the
mTOR pathway in HN6 cells might be linked to mechanisms un-
derlying tumor cell responses to hypoxia through REDD1. As shown
in Figure 3A, REDD1 expression in HN13 cells was markedly up-
regulated after hypoxia; moreover, the increase in hypoxia-induced
Figure 2. Hypoxia inhibits the mTOR pathway in HNSCC cells. (A)
Representative serum-deprived HNSCC cell lines were subjected
to normoxic (N) or hypoxic (H) conditions for 18 hours. Whole cell
extracts were analyzed by Western blot analysis to determine the
effects of hypoxia on the mTOR pathway in vitro. Hypoxia-induced
mTOR substrate dephosphorylation in the HN13 and HN12 cell
lines as judged by the reduction in pS6 expression. In HN6 cells,
however, the mTOR pathway remained hyperactivated under both
normoxic and hypoxic conditions as demonstrated by the sus-
tained expression of pS6 protein. Increased HIF-1α expression
positively validated the response to hypoxia in all three cell lines.
Total S6 and α-tubulin expression are shown as sample loading
controls. (B) The HNSCC cell lines cultured in the presence or ab-
sence of 10% fetal bovine serum were exposed to normoxic or
hypoxic conditions for 18 hours. Whole cell extracts were analyzed
by Western blot analysis to determine the expression levels of
phosphorylated Akt. Total Akt is shown as loading control.
Figure 3. Hypoxic inhibition of the mTOR pathway in HNSCC cells
correlates with REDD1 protein expression levels. (A) Whole cell ex-
tracts from serum-deprived HN13 and HN6 cells exposed to norm-
oxia (N) or hypoxia (H) were subjected toWestern blot analysis with
an antibody against the stress-induced protein REDD1. In HN13
cells, REDD1 was markedly up-regulated by hypoxia, and this re-
sponse correlated with mTOR pathway inhibition as judged by
pS6 dephosphorylation. In contrast, REDD1 expression inHN6 cells
was not induced by hypoxia and S6 remained in its phosphorylated
active form under these conditions. (B) REDD1 protein expression
was knocked-down in HN13 cells through siRNA to further validate
the effects of REDD1 on mTOR activity under hypoxia. HN13 cells
were either left untransfected (−) or transfectedwith a control (C) or
REDD1 siRNA oligonucleotide duplex. Forty-eight hours after trans-
fection, serum-deprived cells were exposed to normoxia or hypoxia
for 18 hours. Western blot analysis shows that in REDD1-depleted
cells hypoxia was unable to induce pS6 dephosphorylation com-
pared to control cells where pS6 expression levels were readily de-
creased. Total S6 levels are shown to assess sample loading. (C)
Following a similar RNAi protocol as described in (B), Western blot
analysis shows that REDD1 expression remained up-regulated in
HIF-1α– or HIF-2α–depleted aswell as untransfected (−) and control
siRNA (C) HN13 cells subjected to hypoxic stress.
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REDD1 seemed to correlate with the down-regulation in pS6 detec-
tion levels. In contrast, however, exposure of HN6 cells to hypoxic
stress did not increase REDD1, and this lack of expression was linked
to a sustained mTOR activity as judged by the levels of pS6, which
remained unchanged when compared to cells maintained in normoxia.
To further examine the role of REDD1 on the regulation of mTOR
activity in HNSCC, HN13 cells were transfected with siRNA oligo-
nucleotide duplexes targeting REDD1. Our findings showed that, in
both untransfected and control siRNA–transfected HNSCC cells,
REDD1 was induced after exposure to hypoxia resulting in mTOR
substrate dephosphorylation. However, when REDD1-depleted cells
were cultured in hypoxic conditions, pS6 expression was comparable
to levels detected in cells grown under normal ambient oxygen, in-
dicating that REDD1 acted as a key negative regulator of mTOR
activity in HNSCC cells (Figure 3B). Previous studies have reported
that in response to hypoxic stress, REDD1 is controlled at the tran-
scriptional level by HIF-1, which acts as the master regulator of
oxygen sensing in mammalian cells [25,26]. Thus, we performed ex-
periments to challenge whether the presence of the oxygen-regulated
α subunit of HIF-1 or HIF-2 was in fact required to control REDD1
expression in HNSCC cells exposed to hypoxia. Surprisingly, we
found that in HN13 cells depleted of HIF-1α or HIF-2α, REDD1
protein expression remained up-regulated, suggesting that under
hypoxic stress, REDD1 might also be controlled at the transcriptional
level by HIF-independent mechanisms (Figure 3C ).
Prolonged Hypoxia Induces Energy Stress and Inhibits the
mTOR Pathway in HNSCC Cells by Activating the
AMPK Pathway
To cope with hypoxia, cells often turn on adaptive mechanisms
that reversibly switch off ATP-consuming processes and switch on
ATP-producing catabolic events to remain viable and survive un-
favorable microenvironmental conditions [27]. These responses are ex-
quisitely controlled by a well-orchestrated intracellular energy-sensing
system governed by the activation of the evolutionarily conserved
AMPK [28]. AMPK is the downstream target of a protein kinase net-
work that is induced by cellular stresses that increase the cellular
AMP/ATP ratio. To be activated, human AMPK requires to be phos-
phorylated at the threonine 172 residue within its catalytic α subunit
[29]. As shown in Figure 4A, HN13 cells cultured under prolonged
hypoxia led to the activation of AMPK and its downstream target
acetyl CoA carboxylase (ACC). As expected, REDD1 expression
was also increased resulting in mTOR substrate dephosphorylation.
Furthermore, a marked reduction in cellular ATP levels supported
these results. Cellular ATP levels were significantly reduced by
74% and 57% when HN13 cells were exposed to hypoxia or to
the energy-depleting AMPK activator 2-DG, respectively (Figure 4B).
Overall, these findings indicated that HNSCC cells under sustained
hypoxic stress triggered responses associated with cellular energy de-
pletion orchestrated through the activation of the AMPK pathway.
mTOR Substrate Dephosphorylation by REDD1 in
Response to Prolonged Hypoxia Requires AMPK
Activation in HNSCC Cells
Recent studies have found that REDD1 is also up-regulated in fi-
broblastic cells undergoing energy stress after either glucose star-
vation or pharmacologically induced ATP depletion, leading to
a TSC1/TSC2–dependent reduction in mTOR activity [19]. It
seems, however, that in these and other cell types, REDD1-mediated
effects on mTOR in response to hypoxia or energy stress do not
depend on AMPK activation [18,20]. For example, when AMPK
is directly activated, REDD1−/− mouse embryonic fibroblasts (MEFs)
failed to down-regulate mTOR activity compared with control
wild type cells, but blocking AMPK activation seems to have no ef-
fect on mTOR substrate dephosphorylation promoted by REDD1
[18–20]. Moreover, REDD1 activation and the subsequent mTOR
substrate dephosphorylation in MEFs exposed to hypoxia is rapid
(within 15 minutes) and occur before any effects on the cellular en-
ergy status [24].
Because the regulatory mechanisms by which cellular stresses such
as hypoxia and energy depletion control mTOR activity seem to be
mediated by two parallel, TSC-dependent pathways, we decided to
explore whether similar mechanisms were also operative in HNSCC
cells. As shown in Figure 5A, hypoxia led to a marked inhibition of
the direct mTOR substrate S6 kinase and its downstream target S6
within 2 hours of hypoxic exposure. These negative effects on the
mTOR pathway correlated with REDD1 up-regulation. Activation
of AMPK, however, occurred solely after prolonged hypoxia as dem-
onstrated by increased phosphorylated forms of AMPK and ACC.
These results suggested that the inhibitory mechanisms affecting
mTOR in HNSCC cells exposed to hypoxia are operating relatively
early and that these processes might be regulated through REDD1 in
an AMPK-independent manner. However, prolonged exposure to
low oxygen levels, a situation likely to occur in the tumor microen-
vironment, results in an energy-depleting response leading to AMPK
activation, thus raising the possibility that hypoxia-induced energy
stress may use AMPK to enhance REDD1 expression, thereby in-
hibiting mTOR function. Indeed, we found that when HN13 cells
were pretreated with compound C, a potent ATP-competitive in-
hibitor of AMPK activation [20], this caused a dramatic inhibition
Figure 4. Hypoxia induces an energy-depleting response in HNSCC
cells by activating the AMPK pathway. (A) Western blot analysis
of whole cell lysates harvested from serum-deprived HN13 cells
grown under normoxic (N) versus hypoxic (H) conditions for 18 hours
shows amarked increase in the phosphorylated status of AMPK and
its downstream target ACC. In addition, hypoxia-induced energy
stress up-regulates REDD1 and affects mTOR activity by prevent-
ing S6 phosphorylation. (B) Cellular ATP levels were determined
by luminescence in total whole cell lysates derived from HN13 cells
cultured under similar conditions as described in (A). The energy-
depleting reagent 2-DG (25 mM for 18 hours) was used as a pos-
itive control for AMPK activation. Representative data from two
independent experiments performed in triplicates and expressed
as the mean ± SEM; *P< .01 and **P< .02 versus normoxic con-
ditions, respectively.
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of REDD1 expression in response to prolonged hypoxia resulting in
hyperphosphorylated levels of S6 similar to the one observed under
basal normoxic conditions (Figure 5B). Similar results were obtained
when both α1 and α2 catalytic subunits of AMPK were depleted by
RNA interference in cells exposed to hypoxia (Figure 5C ). These
findings pointed to the possibility that in our system, AMPK activa-
tion, because of an energy-depleting response triggered by prolonged
hypoxia, is required to fully support REDD1 expression and func-
tion to suppress mTOR activity in HNSCC cells. We also show
evidence, in agreement with previous studies [19,20], that in fact
REDD1 expression in response to hypoxia is not required for AMPK
activation as measured by the increased phosphorylated status of
AMPK and ACC in REDD1-depleted HNSCC cells (Figure 5D).
Thus, in HNSCC cells, AMPK activation after hypoxia-induced en-
ergy stress seems to control an upstream signaling mechanism to pro-
mote the essential inhibitory role of REDD1 on mTOR activity.
These observations indicate that, in HNSCC cells under hypoxic
stress, REDD1 activation is responsible for mediating the inhibitory
mechanisms on the mTOR pathway through AMPK-independent
and -dependent pathways. In response to energy stress induced by
prolonged hypoxia, AMPK activity seems to be critical in controlling
REDD1 expression through a novel yet to be elucidated mechanism
(Figure 6). This activation eventually triggers a response mediated
by the TSC complex to inhibit mTOR activation and, as a con-
sequence, prevents the phosphorylation of its downstream targets
4EBP1 and S6K. It is then plausible that within hypoxic foci in hu-
man HNSCC, the AMPK energy-sensing apparatus and REDD1
may be linked in the control of mTOR activity. Therefore, any distur-
bance in the proper function of these key components, as exemplified
by our findings in HN6 cells, may drive the persistent hyperactiva-
tion of the mTOR pathway in HNSCC and explain in part the toler-
ance to the inhibitory actions of hypoxic stress on this pathway.
Discussion
Significant progress has been achieved in recent years to identify
key molecular signatures involved in the pathogenesis of human
HNSCC [30]. These remarkable efforts have certainly provided a
better understanding of how deregulated signaling pathways involv-
ing oncogenic and tumor-suppressive protein products contribute to
Figure 5. Inhibition of AMPK activation in HNSCC cells blocks hypoxia-induced REDD1 expression and retains mTOR activity. (A) Serum-
depleted HN13 cells were exposed to hypoxia for the indicated times. Western blot analysis showed that AMPK activation and increased
pACC levels occurred only after prolonged hypoxia (18 hours), whereas REDD1 expression and mTOR substrate dephosphorylation, as
judged by pS6K and pS6 levels, were relatively early events. Total S6 served as loading control. (B) HN13 serum-depleted cells pre-
treated with compound C, a potent AMPK inhibitor (10 μM; 30 minutes), or vehicle control and then cultured under normoxic or hypoxic
conditions in the presence or absence of EGF (100 ng/ml) for 18 hours. Note that REDD1 expression under hypoxia was completely
blunted in the absence of AMPK activation, thus sustaining mTOR-activating status. α-tubulin was used as loading control. (C, D) HN13
cells were either left untransfected (−) or transfected with a control (C), AMPKα1/α2 or REDD1 siRNA. Forty-eight hours after transfec-
tions, serum-deprived cells were exposed to normoxia or hypoxia for 18 hours. Western blot analyses show that REDD1 expression is
dependent on the activation status of AMPK (C) but that the activation of the AMPK pathway occurred in a REDD1-independent fashion
(D). GAPDH was used as loading control.
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HNSCC development and progression. More importantly, these
advances offer exciting opportunities to implement in the clinical
setting novel molecularly targeted anticancer therapies [31]. The
epidermal growth factor receptor (EGFR)/Akt/mTOR pathway has
received considerable attention owing to its frequent overactivation
in a large number of HNSCC patients and their derived cell lines
[13,14,16,32]. For instance, the mTOR downstream effector eIF4E
seems to be overexpressed and functionally active in the surgical mar-
gins of HNSCC patients and has been regarded as an independent
risk factor for recurrent disease [16]. Tissue microarray technology
has also provided compelling evidence on the widespread activation
status of the mTOR pathway as judged by an increase in pS6 in
hundreds of human HNSCC specimens [15,33]. Of interest, in a
large subset of cases, mTOR activation occurs independently of
the activation status of the EGFR. Aberrantly activated EGFR often
transduces signals through the Akt/mTOR pathway in several cancer
types. In particular, overexpressed, hyperactive, or mutated EGFRs
have been frequently associated with the development and progres-
sion of HNSCC [32,34–36]. However, it seems that, in a significant
fraction of patients, mTOR activation takes place bypassing EGFR-
dependent growth-stimulatory pathways. These emerging results
present a critical challenge to further explore alternative routes that
may contribute to the hyperactivation of this pathway in HNSCC.
Among multiple intracellular signaling cascades, the mTOR path-
way positions itself as an intricate network of signaling molecules that
respond to a diversity of environmental and nutritional cues to coor-
dinate appropriate cell growth and proliferative responses [37]. As a
consequence, cellular anabolic metabolism is tightly regulated by the
surrounding microenvironment where oxygen availability plays a
profound effect in part by efficiently supporting mTOR pathway–
dependent protein synthesis and mass accumulation [9–11]. In the
case of solid tumors and HNSCC, in particular, hypoxia is a com-
mon microenvironmental stress playing a significant role in promot-
ing treatment resistance and poor patient survival [32,38,39]. If we
draw a parallel between what actually occurs in human tumors,
it seems likely to hypothesize that in a fraction of tumors with aber-
rantly high mTOR pathway dependency, the inhibitory mechanisms
responsible for down-regulating mTOR activity in response to hyp-
oxia are not functioning properly.
Our observations confirmed previously published genetic and bio-
chemical studies reporting that, in response to hypoxia, REDD1 is a
key component within a pathway critical for human tumor suppres-
sion [18–20,24]. However, in contrast to what it has been reported
by these groups in MEFs or HEK293 cells, we observed that, in
HNSCC cells, REDD1 expression is associated with the activation
of AMPK after hypoxia-induced energy stress, supporting the no-
tion that in HNSCC cells, prolonged hypoxia generates an energy-
depleting response orchestrated by the AMPK signaling apparatus.
Hypoxia-induced energy stress has been recently linked to mRNA
translation and cell growth in part by impinging on the mTOR path-
way [11]. These effects seem to be mediated by the activation of
AMPK and TSC2 in an HIF-independent fashion. For example,
under serum-depleted conditions, Liu et al. observed AMPK activa-
tion in HEK293 cells within minutes and up to 20 hours. This was
not the case in our system; on the contrary, we were able to detect
AMPK activation only after prolonged hypoxic stress (18 hours). Al-
though REDD1 expression and function was not assessed in the
study conducted by Liu et al., our data are similar in that the effects
of prolonged hypoxia on mTOR inhibition can occur through
AMPK activation after ATP depletion and independently of HIF-1
accumulation. Our results, however, indicate that under prolonged
hypoxia, AMPK activation is necessary to inhibit mTOR as long
as REDD1 is intact, with the assumption that the TSC complex is
functional, because AMPK activation alone did not result in reduced
mTOR activity. We suggest the possibility that the discrepancy ob-
served with other studies on the dependency of active AMPK on
REDD1 function may be related to the timing of hypoxic exposure
as well as the origin of the cellular system being investigated [18].
The biochemical mechanism by which the TSC complex and
REDD1 interact to inhibit mTOR function has remained elusive.
In a recent study, DeYoung et al. [24], provided compelling evidence
that the mTOR inhibitory mechanisms triggered by hypoxia are in
part mediated by the interaction of TSC2 with 14-3-3 proteins. By
using genetic and biochemical approaches, they show that in the
presence of growth factor–stimulated conditions, 14-3-3 proteins as-
sociate with TSC2 after the activation of the PI3K/Akt signaling
pathway. Under hypoxic conditions, however, REDD1 specifically
prevents PI3K/Akt–induced TSC2/14-3-3 association by binding
14-3-3, which leads to the release of TSC2 from this complex and
promotes mTOR substrate dephosphorylation. Indeed, this novel
mechanism may in part explain the resistance to hypoxia-induced
mTOR inhibition observed in HN6 cells, a HNSCC cell line with
constitutively and robust Akt activation [13]. Emerging studies also
reveal REDD1-independent mechanisms for triggering mTOR inhi-
bition in response to hypoxia. It has been recently identified that by
Figure 6. Proposedmodel for the effects of hypoxia-induced energy
stress on themTOR pathway in HNSCC cells. In response to ATP de-
pletion associated with prolonged hypoxia, REDD1 plays a key role
integrating yet to be elucidated signals that depend on the activation
of the AMPK energy-sensing apparatus to promote mTOR substrate
dephosphorylation in a TSC-dependent fashion. In addition, REDD1
acts as a critical negative regulator of mTOR activity in response to
acute hypoxia independently on the cellular energy status.
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acting directly on Rheb, which is the direct downstream target of
TSC2 and upstream mTOR activator, the hypoxia-inducible Bnip3,
a Bcl-2 homology 3 domain-containing protein, can prevent mTOR
activation by Rheb [40]. Further studies are definitely warranted in
general but especially in the context of HNSCC cancer biology
where the interplay between hypoxia and the mTOR pathway is a
common element affecting the progression of the disease. In this
regard, the elucidation of the basic mechanisms affecting this net-
work of signaling molecules will offer essential information to better
understand and support the pharmacological mechanism-based ap-
plication of mTOR inhibitors, alone or in combination with other
targeted therapies as well as conventional treatments to halt the de-
velopment and progression of HNSCC.
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